Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
What changed & why it matters
MedSpaRadar recorded a regulatory change at the federal level, dated September 15, 2026, in the GLP-1 Compounding category.
This change is tracked for its potential impact on med-spa and injectable practice — what a practice may do, who may perform it, and from whom product may be sourced.
- Type
- Primary Source Monitoring
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Recorded
- September 15, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
Primary Source Monitoring · primary source ↗
Get regulatory changes as they publish
We scan all 50 state legislatures daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
Related alerts
- Source qualification pending
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- Source qualification pending
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA Warning Letter: Fresenius Kabi Compounding, LLC (Drugs)
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.